PharmAI and NanoTemper Technologies cooperate

The Dresden-based start-up and the Munich-based company both want to develop drugs faster. Their plan: to better research rare diseases.

Dresden-based start-up PharmAI is teaming up with Munich-based NanoTemper Technologies. Together, the two want to develop tools for analyzing large amounts of data generated in drug research. With these, the two companies believe, smaller labs could get into drug discovery and better research rare diseases.

NanoTemper Technologies has focused on the analysis of biomolecules. Specifically, NanoTemper can determine, for example, the size, composition or even durability of biomolecules. Dresden-based start-up PharmAI, on the other hand, aims to use artificial intelligence to fish out new drug candidates from big data. "Our software makes helpful predictions about drug candidates and reduces millions of possibilities to a manageable size," says Joachim Haupt, head of PharmAI. In the future, NanoTemper will validate these results. Philipp Baaske, co-managing director at NanoTemper explains, "Customers don't want to spend time dealing with measured values, they want to gain new insights and use them in their work. That's exactly what we help with."

PharmAI has been on the market since 2019 and is a spin-off of the Technical University of Dresden. According to its own information, it analyzes 3D protein structures with the help of artificial intelligence and aims to make drug development more efficient.